A 2–4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01
- 1 December 2017
- journal article
- research article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 33 (12) , 1248-1257
Abstract
The envelope glycoprotein (Env) gp120 of human immunodeficiency virus type 1 (HIV-1) plays a critical role in viral entry into host cells. The broadly neutralizing human monoclonal antibody VRC01, which recognizes the CD4 binding site on gp120, neutralizes more than 90% of HIV-1 isolates. However, some of the CRF01_AE viruses prevalent in Southeast Asia are resistant to VRC01-mediated neutralization. We previously reported that 3 amino acid residues at positions 185, 186, and 197 of gp120 played an important role in the VRC01 resistance of CRF01_AE Env (AE-Env) clones isolated from HIV-infected Thai individuals. However, the VRC01 susceptibility of AE-Env clones was not fully explained by mutations at these 3 residues. In the present study, we examined other factors involved in the acquisition of viral VRC01 resistance. Neutralization tests using lentiviral vectors expressing a series of mutant AE-Env clones revealed that the deletion of 2–4 amino acid residues on the loop structure in the V5 region of gp120 conferred VRC01 resistance to several AE-Env clones. Our results provide novel insights into the mechanisms underlying viral VRC01 resistance.Keywords
This publication has 27 references indexed in Scilit:
- Non-M Variants of Human Immunodeficiency Virus Type 1Clinical Microbiology Reviews, 2013
- Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance, and the Success of HIV Treatment ProgramsThe Journal of Infectious Diseases, 2013
- Broadly neutralizing antibodies against HIV-1: Templates for a vaccineVirology, 2013
- HIV-1 Antiretroviral Drug TherapyCold Spring Harbor Perspectives in Medicine, 2012
- Global trends in molecular epidemiology of HIV-1 during 2000–2007AIDS, 2011
- Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1Science, 2010
- Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 InfectionJournal of Virology, 2009
- The Challenge of HIV-1 Subtype DiversityNew England Journal of Medicine, 2008
- Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic ImplicationsJournal of Virology, 2007
- The Emerging Genetic Diversity of HIVJAMA, 1996